Literature DB >> 17277779

The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease.

Youcun Qian1, Caini Liu, Justin Hartupee, Cengiz Zubeyir Altuntas, Muhammet Fatih Gulen, Daniel Jane-Wit, Jianhua Xiao, Yi Lu, Natalia Giltiay, Jinbo Liu, Tomasz Kordula, Qi-Wei Zhang, Bruce Vallance, Shadi Swaidani, Mark Aronica, Vincent K Tuohy, Thomas Hamilton, Xiaoxia Li.   

Abstract

T helper cells that produce interleukin 17 (IL-17) are associated with inflammation and the control of certain bacteria. We report here the essential involvement of the adaptor protein Act1 in IL-17 receptor (IL-17R) signaling and IL-17-dependent immune responses. After stimulation with IL-17, recruitment of Act1 to IL-17R required the IL-17R conserved cytoplasmic 'SEFIR' domain, followed by recruitment of the kinase TAK1 and E3 ubiquitin ligase TRAF6, which mediate 'downstream' activation of transcription factor NF-kappaB. IL-17-induced expression of inflammation-related genes was abolished in Act1-deficient primary astroglial and gut epithelial cells. This reduction was associated with much less inflammatory disease in vivo in both autoimmune encephalomyelitis and dextran sodium sulfate-induced colitis. Our data show that Act1 is essential in IL-17-dependent signaling in autoimmune and inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17277779     DOI: 10.1038/ni1439

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  268 in total

1.  The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α.

Authors:  Shu Zhu; Wen Pan; Xinyang Song; Yan Liu; Xinrui Shao; Yuanjia Tang; Dong Liang; Dongyi He; Honglin Wang; Wenjun Liu; Yufang Shi; John B Harley; Nan Shen; Youcun Qian
Journal:  Nat Med       Date:  2012-07       Impact factor: 53.440

Review 2.  Interleukin-23 and T helper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity.

Authors:  Peter J Morrison; Sarah J Ballantyne; Marika C Kullberg
Journal:  Immunology       Date:  2011-06-02       Impact factor: 7.397

Review 3.  Cytokine regulation of B-cell migratory behavior favors formation of germinal centers in autoimmune disease.

Authors:  John D Mountz; John H Wang; Shutao Xie; Hui-Chen Hsu
Journal:  Discov Med       Date:  2011-01       Impact factor: 2.970

4.  [Genetics of common chronic inflammatory skin diseases : An update on atopic dermatitis and psoriasis].

Authors:  E Rodríguez; K Eyerich; S Weidinger
Journal:  Hautarzt       Date:  2011-02       Impact factor: 0.751

Review 5.  A tale of two cytokines: IL-17 and IL-22 in asthma and infection.

Authors:  Michelle L Manni; Keven M Robinson; John F Alcorn
Journal:  Expert Rev Respir Med       Date:  2013-12-10       Impact factor: 3.772

6.  IL-17 signaling-independent central nervous system autoimmunity is negatively regulated by TGF-beta.

Authors:  Ines Gonzalez-García; Yani Zhao; Songguang Ju; Qin Gu; Lin Liu; Jay K Kolls; Binfeng Lu
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 7.  IL-17 in the lung: the good, the bad, and the ugly.

Authors:  Stephen J Gurczynski; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-31       Impact factor: 5.464

Review 8.  IL-17F: regulation, signaling and function in inflammation.

Authors:  Seon Hee Chang; Chen Dong
Journal:  Cytokine       Date:  2009-02-23       Impact factor: 3.861

9.  Artificial Macrocycles as IL-17A/IL-17RA Antagonists.

Authors:  Wenjia Wang; Matthew R Groves; Alexander Dömling
Journal:  Medchemcomm       Date:  2017-10-25       Impact factor: 3.597

10.  IL-17RD (Sef or IL-17RLM) interacts with IL-17 receptor and mediates IL-17 signaling.

Authors:  Zhili Rong; Anan Wang; Zhiyong Li; Yongming Ren; Long Cheng; Yinghua Li; Yinyin Wang; Fangli Ren; Xiaoning Zhang; Jim Hu; Zhijie Chang
Journal:  Cell Res       Date:  2009-02       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.